While termination of the ABX464 COViD Phase 2b / 3 miRAGE trial is clearly a disappointment, we see little read-through to the core ABX464 programmes in chronic inflammation. The basis of the acute inflammatory storm in patients with severe COVID remains poorly understood. These negative data likely reflect the distinct natures of acute and chronic inflammatory disease, where strong Phase 2 data in ulcerative colitis already supports ABX464 safety and efficacy. Abivax remains substantially unde ....
09 Mar 2021
COVID disappointment of little relevance to chronic programmes
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
COVID disappointment of little relevance to chronic programmes
Abivax SA (0RA9:LON) | 0 0 0.5% | Mkt Cap: 83.0m
- Published:
09 Mar 2021 -
Author:
Chris Redhead -
Pages:
5
While termination of the ABX464 COViD Phase 2b / 3 miRAGE trial is clearly a disappointment, we see little read-through to the core ABX464 programmes in chronic inflammation. The basis of the acute inflammatory storm in patients with severe COVID remains poorly understood. These negative data likely reflect the distinct natures of acute and chronic inflammatory disease, where strong Phase 2 data in ulcerative colitis already supports ABX464 safety and efficacy. Abivax remains substantially unde ....